Identification	O
of	O
gene	O
expression	O
patterns	O
crucially	O
involved	O
in	O
experimental	B-DS
autoimmune	I-DS
encephalomyelitis	I-DS
and	O
multiple	B-DS
sclerosis	I-DS

ABSTRACT	O

After	O
encounter	O
with	O
a	O
central	O
nervous	O
system	O
(	O
CNS	O
)-	O
derived	O
autoantigen	O
,	O
lymphocytes	O
leave	O
the	O
lymph	O
nodes	O
and	O
enter	O
the	O
CNS	O
.	O

This	O
event	O
leads	O
only	O
rarely	O
to	O
subsequent	O
tissue	O
damage	O
.	O

Genes	O
relevant	O
to	O
CNS	O
pathology	O
after	O
cell	O
infiltration	O
are	O
largely	O
undefined	O
.	O

Myelin	B-GP
-	I-GP
oligodendrocyte	I-GP
-	I-GP
glycoprotein	I-GP
(	O
MOG	B-GP
)-	O
induced	O
experimental	B-DS
autoimmune	I-DS
encephalomyelitis	I-DS
(	O
EAE	B-DS
)	O
is	O
an	O
animal	B-OG
model	O
of	O
multiple	B-DS
sclerosis	I-DS
(	O
MS	B-DS
),	O
a	O
chronic	B-DS
autoimmune	I-DS
disease	I-DS
of	O
the	O
CNS	O
that	O
results	O
in	O
disability	O
.	O

To	O
assess	O
genes	O
that	O
are	O
involved	O
in	O
encephalitogenicity	O
and	O
subsequent	O
tissue	O
damage	O
mediated	O
by	O
CNS	O
-	O
infiltrating	O
cells	O
,	O
we	O
performed	O
a	O
DNA	O
microarray	O
analysis	O
from	O
cells	O
derived	O
from	O
lymph	O
nodes	O
and	O
eluted	O
from	O
CNS	O
in	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
MOG	B-GP
91	O
-	O
108	O
.	O

The	O
data	O
was	O
compared	O
to	O
immunizations	O
with	O
adjuvant	O
alone	O
or	O
naive	O
rats	B-OG
and	O
to	O
immunizations	O
with	O
the	O
immunogenic	O
but	O
not	O
encephalitogenic	O
MOG	B-GP
73	O
-	O
90	O
peptide	O
.	O

Here	O
,	O
we	O
show	O
involvement	O
of	O
Cd38	B-GP
,	O
Cxcr4	B-GP
and	O
Akt	B-GP
and	O
confirm	O
these	O
findings	O
by	O
the	O
use	O
of	O
Cd38	B-GP
-	O
knockout	O
(	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
)	O
mice	B-OG
,	O
S1P	B-GP
-	I-GP
receptor	I-GP
modulation	O
during	O
EAE	B-DS
and	O
quantitative	O
expression	O
analysis	O
in	O
individuals	O
with	O
MS	B-DS
.	O

The	O
hereby	O
-	O
defined	O
underlying	O
pathways	O
indicate	O
cellular	O
activation	O
and	O
migration	O
pathways	O
mediated	O
by	O
G	B-GP
-	I-GP
protein	I-GP
-	I-GP
coupled	I-GP
receptors	I-GP
as	O
crucial	O
events	O
in	O
CNS	O
tissue	O
damage	O
.	O

These	O
pathways	O
can	O
be	O
further	O
explored	O
for	O
novel	O
therapeutic	O
interventions	O
.	O

Summary	O
:	O
To	O
define	O
disease	O
-	O
inducing	O
immune	O
responses	O
,	O
unbiased	O
gene	O
expression	O
in	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
autoantigen	O
-	O
derived	O
encephalitogenic	O
and	O
non	O
-	O
encephalitogenic	O
peptides	O
was	O
investigated	O
in	O
MOG	B-GP
-	O
EAE	B-DS
.	O

CXCR4	B-GP
,	O
CXCL12	B-GP
,	O
AKT	B-GP
and	O
CD38	B-GP
control	O
CNS	O
inflammation	O
.	O

INTRODUCTION	O

Multiple	B-DS
sclerosis	I-DS
(	O
MS	B-DS
)	O
is	O
a	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
that	O
leads	O
to	O
chronic	O
inflammation	O
,	O
demyelination	O
,	O
and	O
axonal	O
and	O
neuronal	O
loss	O
,	O
resulting	O
in	O
disability	O
(	O
Noseworthy	O
et	O
al	O
.,	O
2000	O
;	O
Weissert	O
,	O
2013	O
).	O

Myelin	B-GP
-	I-GP
oligodendrocyte	I-GP
-	I-GP
glycoprotein	I-GP
(	O
MOG	B-GP
)-	O
induced	O
experimental	B-DS
autoimmune	I-DS
encephalomyelitis	I-DS
(	O
EAE	B-DS
)	O
in	O
rats	B-OG
reproduces	O
major	O
aspects	O
of	O
the	O
human	B-OG
pathology	O
(	O
Weissert	O
et	O
al	O
.,	O
1998b	O
;	O
Storch	O
et	O
al	O
.,	O
1998	O
;	O
Kornek	O
et	O
al	O
.,	O
2000	O
;	O
Weissert	O
,	O
2016	O
).	O

MOG	B-GP
is	O
expressed	O
on	O
the	O
outer	O
surface	O
of	O
the	O
myelin	O
sheath	O
.	O

In	O
contrast	O
to	O
merely	O
T	O
-	O
cell	O
-	O
mediated	O
animal	B-OG
models	O
,	O
the	O
pathogenesis	O
of	O
MOG	B-GP
-	O
induced	O
EAE	B-DS
in	O
the	O
rat	B-OG
involves	O
the	O
combined	O
action	O
of	O
T	O
and	O
B	O
cells	O
,	O
antibodies	B-GP
and	O
macrophages	O
,	O
mimicking	O
type	O
II	O
lesions	O
in	O
MS	B-DS
(	O
Genain	O
et	O
al	O
.,	O
1995	O
;	O
Mathey	O
et	O
al	O
.,	O
2004	O
;	O
Lucchinetti	O
et	O
al	O
.,	O
2000	O
).	O

Encephalitogenic	O
peptides	O
presented	O
on	O
MHC	B-GP
class	I-GP
II	I-GP
molecules	O
to	O
T	O
cells	O
lead	O
to	O
a	O
program	O
that	O
forces	O
lymphocytes	O
to	O
be	O
activated	O
and	O
migrate	O
towards	O
the	O
CNS	O
(	O
Riedhammer	O
and	O
Weissert	O
,	O
2015	O
).	O

Adjuvant	O
contributes	O
by	O
affecting	O
multiple	O
signaling	O
pathways	O
in	O
lymphocytes	O
as	O
well	O
as	O
in	O
organ	O
-	O
resident	O
cells	O
like	O
in	O
the	O
CNS	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
MOG	B-GP
91	O
-	O
108	O
is	O
the	O
major	O
determinant	O
to	O
trigger	O
disease	O
in	O
rats	B-OG
expressing	O
RT1av1	O
or	O
RT1n	O
haplotypes	O
(	O
Weissert	O
et	O
al	O
.,	O
2001	O
).	O

Interestingly	O
,	O
the	O
capacity	O
of	O
MOG	B-GP
91	O
-	O
108	O
to	O
induce	O
EAE	B-DS
was	O
dissociated	O
in	O
regard	O
to	O
Th1	O
or	O
Th2	O
cytokine	B-GP
expression	O
in	O
lymphoid	O
tissue	O
compared	O
to	O
the	O
CNS	O
.	O

Moreover	O
,	O
different	O
MOG	B-GP
1	O
-	O
125	O
-	O
derived	O
peptides	O
,	O
such	O
as	O
MOG	B-GP
73	O
-	O
90	O
,	O
were	O
immunogenic	O
,	O
showing	O
strong	O
Th1	O
responses	O
,	O
but	O
were	O
not	O
encephalitogenic	O
.	O

The	O
induction	O
of	O
active	O
EAE	B-DS
in	O
LEW	O
MHC	B-GP
congenic	O
rat	B-OG
strains	O
and	O
Dark	O
Agouti	O
(	O
DA	O
)	O
(	O
RT1av1	O
)	O
rats	B-OG
does	O
not	O
require	O
the	O
application	O
of	O
pertussis	B-GP
toxin	I-GP
like	O
in	O
mice	B-OG
.	O

This	O
is	O
an	O
advantage	O
because	O
the	O
exact	O
role	O
of	O
pertussis	B-GP
toxin	I-GP
in	O
EAE	B-DS
induction	O
is	O
not	O
clear	O
so	O
far	O
.	O

Pertussis	B-GP
toxin	I-GP
inhibits	O
Gi	B-GP
proteins	I-GP
and	O
thereby	O
influences	O
multiple	O
cellular	O
processes	O
and	O
pathways	O
(	O
Dumas	O
et	O
al	O
.,	O
2014	O
).	O

Active	O
EAE	B-DS
in	O
susceptible	O
rat	B-OG
strains	O
is	O
induced	O
by	O
immunization	O
with	O
an	O
encephalitogenic	O
peptide	O
mixed	O
with	O
mineral	O
oil	O
[	O
incomplete	O
Freund	O
'	O
s	O
adjuvant	O
(	O
IFA	O
)]	O
with	O
the	O
addition	O
of	O
heat	O
-	O
inactivated	O
mycobacterium	B-OG
tuberculosis	I-OG
(	O
MT	B-OG
)	O
as	O
adjuvant	O
[	O
complete	O
Freund	O
'	O
s	O
adjuvant	O
(	O
CFA	O
)].	O

MT	B-OG
leads	O
by	O
binding	O
and	O
signaling	O
through	O
Toll	B-GP
-	I-GP
like	I-GP
receptors	I-GP
(	O
TLRs	B-GP
)	O
to	O
an	O
activation	O
program	O
in	O
a	O
number	O
of	O
cell	O
types	O
and	O
is	O
also	O
a	O
systemic	O
‘	O
danger	O
signal	O
’	O
(	O
Mills	O
,	O
2011	O
).	O

In	O
regard	O
to	O
susceptibility	O
to	O
EAE	B-DS
and	O
MS	B-DS
,	O
gene	O
expression	O
profiling	O
studies	O
have	O
been	O
performed	O
to	O
elucidate	O
genes	O
that	O
are	O
involved	O
in	O
disease	O
pathogenesis	O
.	O

A	O
number	O
of	O
interesting	O
genes	O
were	O
described	O
,	O
such	O
as	O
osteopontin	B-GP
(	O
Hur	O
et	O
al	O
.,	O
2007	O
).	O

In	O
no	O
study	O
was	O
a	O
systematic	O
comparison	O
of	O
gene	O
expression	O
profiles	O
performed	O
in	O
EAE	B-DS
in	O
which	O
the	O
influence	O
of	O
adjuvant	O
and	O
antigen	O
was	O
systematically	O
compared	O
on	O
the	O
expression	O
profile	O
of	O
lymph	O
node	O
(	O
LN	O
)-	O
derived	O
cells	O
or	O
cells	O
eluted	O
from	O
CNS	O
of	O
diseased	O
animals	B-OG
.	O

In	O
the	O
present	O
study	O
,	O
we	O
systematically	O
compared	O
the	O
gene	O
expression	O
profiles	O
of	O
cells	O
from	O
draining	O
LNs	O
and	O
CNS	O
-	O
infiltrating	O
cells	O
that	O
were	O
eluted	O
in	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
MOG	B-GP
91	O
-	O
108	O
in	O
CFA	O
,	O
CFA	O
alone	O
and	O
in	O
naive	O
rats	B-OG
.	O

Moreover	O
,	O
we	O
compared	O
the	O
gene	O
expression	O
profile	O
of	O
rats	B-OG
immunized	O
with	O
the	O
encephalitogenic	O
MOG	B-GP
peptide	O
91	O
-	O
108	O
with	O
rats	B-OG
immunized	O
with	O
the	O
non	O
-	O
encephalitogenic	O
MOG	B-GP
peptide	O
73	O
-	O
90	O
.	O

We	O
found	O
differentially	O
expressed	O
genes	O
that	O
are	O
of	O
major	O
importance	O
for	O
encephalitogenicity	O
.	O

The	O
influence	O
of	O
these	O
genes	O
was	O
subsequently	O
verified	O
by	O
different	O
means	O
.	O

RESULTS	O

Gene	O
expression	O
after	O
immunization	O
with	O
encephalitogenic	O
and	O
non	O
-	O
encephalitogenic	O
peptides	O

One	O
of	O
the	O
important	O
issues	O
in	O
MS	B-DS
and	O
other	O
inflammatory	B-DS
diseases	I-DS
of	O
the	O
CNS	O
is	O
understanding	O
the	O
requisites	O
of	O
autoantigenic	O
peptides	O
to	O
induce	O
CNS	O
inflammation	O
(	O
Riedhammer	O
and	O
Weissert	O
,	O
2015	O
).	O

Beside	O
presentation	O
of	O
autoantigen	O
-	O
derived	O
peptides	O
on	O
MHC	B-GP
molecules	O
and	O
the	O
availability	O
of	O
reactive	O
T	O
-	O
cell	O
and	O
B	O
-	O
cell	O
repertoires	O
as	O
well	O
as	O
the	O
presence	O
of	O
the	O
target	O
antigen	O
in	O
the	O
CNS	O
,	O
pathways	O
of	O
cellular	O
activation	O
exist	O
that	O
allow	O
disease	O
development	O
.	O

These	O
pathways	O
are	O
presently	O
only	O
partly	O
elucidated	O
.	O

We	O
used	O
MOG	B-GP
-	O
induced	O
EAE	B-DS
in	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
as	O
a	O
model	O
system	O
for	O
CNS	O
inflammation	O
.	O

In	O
this	O
EAE	B-DS
model	O
,	O
the	O
determinant	O
MOG	B-GP
91	O
-	O
108	O
is	O
immunogenic	O
and	O
encephalitogenic	O
.	O

In	O
contrast	O
,	O
the	O
determinant	O
MOG	B-GP
73	O
-	O
90	O
is	O
immunogenic	O
but	O
not	O
encephalitogenic	O
.	O

We	O
assessed	O
the	O
gene	O
expression	O
profiles	O
by	O
gene	O
arrays	O
of	O
lymphocytes	O
from	O
draining	O
LNs	O
and	O
from	O
lymphocytes	O
eluted	O
from	O
the	O
CNS	O
.	O

To	O
focus	O
on	O
genes	O
that	O
are	O
truly	O
relevant	O
to	O
encephalitogenicity	O
and	O
not	O
simply	O
involved	O
in	O
general	O
inflammatory	O
responses	O
,	O
we	O
compared	O
gene	O
arrays	O
of	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
the	O
encephalitogenic	O
MOG	B-GP
stretch	O
MOG	B-GP
91	O
-	O
108	O
to	O
naive	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
and	O
rats	B-OG
immunized	O
with	O
the	O
adjuvant	O
CFA	O
alone	O
as	O
well	O
as	O
rats	B-OG
immunized	O
with	O
the	O
non	O
-	O
encephalitogenic	O
MOG	B-GP
73	O
-	O
90	O
determinant	O
.	O

We	O
analyzed	O
ten	O
comparisons	O
for	O
each	O
of	O
the	O
naive	O
and	O
CFA	O
groups	O
versus	O
MOG	B-GP
91	O
-	O
108	O
and	O
five	O
comparisons	O
for	O
MOG	B-GP
73	O
-	O
90	O
versus	O
MOG	B-GP
91	O
-	O
108	O
.	O

The	O
number	O
of	O
comparisons	O
in	O
which	O
a	O
given	O
gene	O
had	O
a	O
signal	O
log	O
ratio	O
(	O
SLR	O
)	O
of	O
above	O
1	O
was	O
counted	O
.	O

In	O
Table	O
1	O
,	O
we	O
show	O
genes	O
that	O
are	O
upregulated	O
in	O
at	O
least	O
half	O
of	O
the	O
comparisons	O
(=	O
50	O
%).	O

Besides	O
Cxcr4	B-GP
and	O
Cd38	B-GP
,	O
which	O
were	O
subsequently	O
analyzed	O
in	O
greater	O
detail	O
,	O
many	O
genes	O
with	O
a	O
known	O
function	O
in	O
EAE	B-DS
and	O
MS	B-DS
pathology	O
were	O
found	O
to	O
have	O
an	O
increased	O
expression	O
in	O
MOG	B-GP
91	O
-	O
108	O
-	O
immunized	O
rats	B-OG
as	O
compared	O
to	O
controls	O
.	O

This	O
validates	O
our	O
gene	O
list	O
and	O
supports	O
the	O
relevance	O
of	O
the	O
genes	O
not	O
previously	O
described	O
in	O
EAE	B-DS
.	O

In	O
Table	O
S1	O
,	O
genes	O
with	O
decreased	O
expression	O
in	O
EAE	B-DS
are	O
listed	O
.	O

In	O
this	O
analysis	O
,	O
the	O
variability	O
between	O
gene	O
arrays	O
was	O
much	O
higher	O
and	O
fewer	O
genes	O
were	O
found	O
to	O
be	O
regulated	O
with	O
a	O
clear	O
pattern	O
according	O
to	O
our	O
criteria	O
.	O
Table	O
1	O
.	O
Genes	O
with	O
increased	O
expression	O
in	O
lymph	O
-	O
node	O
cells	O
of	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG

Comparisons	O
of	O
microarrays	O
of	O
CNS	O
-	O
infiltrating	O
lymphocytes	O
derived	O
from	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
after	O
immunization	O
with	O
MOG	B-GP
91	O
-	O
108	O
,	O
MOG	B-GP
73	O
-	O
90	O
and	O
CFA	O
alone	O
resulted	O
in	O
many	O
more	O
genes	O
being	O
differentially	O
expressed	O
as	O
compared	O
to	O
the	O
analysis	O
of	O
LN	O
cells	O
(	O
Tables	O
S2	O
and	O
S3	O
).	O

This	O
could	O
mirror	O
the	O
influx	O
of	O
different	O
cell	O
populations	O
into	O
the	O
CNS	O
during	O
an	O
inflammatory	O
attack	O
.	O

Similar	O
to	O
the	O
analysis	O
of	O
LN	O
cells	O
,	O
we	O
found	O
that	O
Cd38	B-GP
and	O
Cxcr4	B-GP
mRNA	O
was	O
strongly	O
increased	O
in	O
CNS	O
-	O
infiltrating	O
cells	O
.	O

Subsequently	O
,	O
we	O
analyzed	O
purified	O
CD4	B-GP
+	O
cells	O
from	O
LNs	O
and	O
CNS	O
of	O
MOG	B-GP
91	O
-	O
108	O
-	O
and	O
MOG	B-GP
73	O
-	O
90	O
-	O
immunized	O
rats	B-OG
.	O

To	O
some	O
extent	O
,	O
similar	O
gene	O
expression	O
profiles	O
were	O
found	O
in	O
the	O
purified	O
CD4	B-GP
+	O
cell	O
population	O
compared	O
to	O
non	O
-	O
separated	O
LN	O
cells	O
(	O
Table	O
1	O
,	O
Tables	O
S4	O
and	O
S5	O
).	O

Owing	O
to	O
their	O
strong	O
expression	O
in	O
MOG	B-GP
91	O
-	O
108	O
-	O
immunized	O
rats	B-OG
compared	O
to	O
naive	O
,	O
CFA	O
-	O
immunized	O
and	O
MOG	B-GP
73	O
-	O
90	O
-	O
immunized	O
rats	B-OG
,	O
we	O
chose	O
Cxcr4	B-GP
and	O
Cd38	B-GP
for	O
further	O
analysis	O
.	O

Cxcr4	B-GP
and	O
Cd38	B-GP
in	O
EAE	B-DS
in	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG

Confirming	O
our	O
microarray	O
results	O
by	O
quantitative	O
PCR	O
,	O
we	O
found	O
a	O
significant	O
upregulation	O
of	O
Cxcr4	B-GP
expression	O
in	O
LN	O
cells	O
of	O
MOG	B-GP
91	O
-	O
108	O
-	O
immunized	O
rats	B-OG
(	O
n	O
=	O
8	O
)	O
as	O
compared	O
to	O
CFA	O
-	O
immunized	O
(	O
n	O
=	O
8	O
,	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
naive	O
(	O
n	O
=	O
6	O
,	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
(	O
Fig	O
.	O
1A	O
).	O

Also	O
,	O
an	O
increased	O
expression	O
of	O
Cd38	B-GP
was	O
measured	O
[	O
MOG	B-GP
91	O
-	O
108	O
-	O
immunized	O
rats	B-OG
(	O
n	O
=	O
8	O
)	O
as	O
compared	O
to	O
CFA	O
-	O
immunized	O
(	O
n	O
=	O
8	O
,	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
naive	O
(	O
n	O
=	O
6	O
,	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
].	O
Fig	O
.	O
1	O
.	O
Cxcr4	B-GP
and	O
Cd38	B-GP
expression	O
in	O
lymph	O
node	O
cells	O
and	O
CNS	O
.	O
(	O
A	O
)	O
Quantitative	O
SYBR	O
green	O
real	O
-	O
time	O
PCR	O
was	O
performed	O
for	O
Cxcr4	B-GP
and	O
Cd38	B-GP
in	O
lymph	O
node	O
(	O
LN	O
)	O
cells	O
from	O
naive	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
(	O
black	O
bars	O
,	O
n	O
=	O
6	O
),	O
or	O
those	O
immunized	O
with	O
CFA	O
(	O
gray	O
bars	O
,	O
n	O
=	O
8	O
)	O
or	O
MOG	B-GP
91	O
-	O
108	O
in	O
CFA	O
(	O
white	O
bars	O
,	O
n	O
=	O
8	O
),	O
on	O
day	O
12	O
p	O
.	O
i	O
.	O

Increased	O
Cxcr4	B-GP
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
Cd38	B-GP
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
)	O
expression	O
was	O
found	O
in	O
MOG	B-GP
91	O
-	O
108	O
in	O
CFA	O
-	O
immunized	O
rats	B-OG
compared	O
to	O
naive	O
and	O
CFA	O
-	O
alone	O
-	O
immunized	O
rats	B-OG
.	O

(	O
B	O
)	O
Quantitative	O
expression	O
of	O
Cxcr4	B-GP
in	O
cells	O
eluted	O
from	O
the	O
CNS	O
of	O
CFA	O
(	O
white	O
bars	O
,	O
n	O
=	O
6	O
)-,	O
MOG	B-GP
73	O
-	O
90	O
in	O
CFA	O
(	O
gray	O
bars	O
,	O
n	O
=	O
6	O
)-	O
and	O
MOG	B-GP
91	O
-	O
108	O
in	O
CFA	O
(	O
n	O
=	O
6	O
)-	O
immunized	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
.	O
Cxcr4	B-GP
was	O
upregulated	O
in	O
MOG	B-GP
91	O
-	O
108	O
in	O
CFA	O
-	O
immunized	O
rats	B-OG
compared	O
to	O
the	O
other	O
groups	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
001	O
)	O
on	O
day	O
12	O
p	O
.	O
i	O
.	O

(	O
C	O
)	O
Quantitative	O
expression	O
of	O
Cd38	B-GP
of	O
lymphocytes	O
eluted	O
from	O
the	O
CNS	O
of	O
CFA	O
(	O
white	O
bars	O
,	O
n	O
=	O
6	O
)-,	O
MOG	B-GP
73	O
-	O
90	O
in	O
CFA	O
(	O
gray	O
bars	O
,	O
n	O
=	O
6	O
)-	O
and	O
MOG	B-GP
91	O
-	O
108	O
in	O
CFA	O
(	O
n	O
=	O
6	O
)-	O
immunized	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
on	O
day	O
12	O
p	O
.	O
i	O
.	O
Cd38	B-GP
was	O
upregulated	O
in	O
MOG	B-GP
91	O
-	O
108	O
in	O
CFA	O
-	O
immunized	O
rats	B-OG
compared	O
to	O
the	O
other	O
groups	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
001	O
).	O

Results	O
are	O
expressed	O
as	O
2	O
−	O
ΔΔ	O
CT	O
values	O
.	O

Numbers	O
are	O
mean	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O

In	O
cells	O
eluted	O
from	O
the	O
CNS	O
,	O
we	O
found	O
upregulation	O
of	O
Cxcr4	B-GP
(	O
Fig	O
.	O
1B	O
)	O
and	O
Cd38	B-GP
(	O
Fig	O
.	O
1C	O
)	O
in	O
MOG	B-GP
91	O
-	O
108	O
-	O
immunized	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
(	O
n	O
=	O
6	O
)	O
compared	O
to	O
rats	B-OG
immunized	O
with	O
MOG	B-GP
73	O
-	O
90	O
(	O
n	O
=	O
6	O
,	O
ANOVA	O
,	O
Cxcr4	B-GP
and	O
Cd38	B-GP
each	O
P	O
<	O
0	O
.	O
001	O
)	O
or	O
CFA	O
alone	O
(	O
n	O
=	O
6	O
,	O
ANOVA	O
,	O
Cxcr4	B-GP
and	O
Cd38	B-GP
each	O
P	O
<	O
0	O
.	O
001	O
).	O

Cxcr4	B-GP
and	O
Cxcl12	B-GP
expression	O
in	O
spinal	O
cord	O
of	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG

Next	O
,	O
we	O
assessed	O
the	O
mRNA	O
expression	O
of	O
Cxcr4	B-GP
(	O
Fig	O
.	O
2A	O
)	O
and	O
its	O
ligand	O
Cxcl12	B-GP
(	O
Fig	O
.	O
2B	O
)	O
in	O
spinal	O
cord	O
of	O
either	O
naive	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
or	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
IFA	O
or	O
CFA	O
alone	O
or	O
MOG	B-GP
1	O
-	O
125	O
in	O
IFA	O
or	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
(	O
each	O
n	O
=	O
4	O
).	O

Upregulation	O
of	O
both	O
Cxcl12	B-GP
and	O
Cxcr4	B-GP
mRNA	O
expression	O
was	O
observed	O
in	O
CFA	O
-	O
and	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
-	O
immunized	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
in	O
spinal	O
cord	O
compared	O
to	O
naive	O
rats	B-OG
,	O
IFA	O
-	O
injected	O
or	O
MOG	B-GP
1	O
-	O
125	O
in	O
IFA	O
-	O
immunized	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

Increased	O
Cxcl12	B-GP
and	O
Cxcr4	B-GP
mRNA	O
expression	O
was	O
observed	O
in	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
-	O
compared	O
to	O
CFA	O
-	O
immunized	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
01	O
).	O
Fig	O
.	O
2	O
.	O
Cxr4	B-GP
and	O
Cxcl12	B-GP
expression	O
in	O
spinal	O
cord	O
of	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
.	O
Quantitative	O
SYBR	O
green	O
real	O
-	O
time	O
PCR	O
was	O
performed	O
for	O
Cxcr4	B-GP
(	O
A	O
)	O
and	O
Cxcl12	B-GP
(	O
B	O
)	O
from	O
PBS	O
-	O
perfused	O
spinal	O
cord	O
tissue	O
of	O
naive	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
(	O
n	O
=	O
4	O
),	O
rats	B-OG
immunized	O
with	O
IFA	O
(	O
n	O
=	O
4	O
)	O
or	O
CFA	O
alone	O
(	O
n	O
=	O
4	O
)	O
and	O
DA	O
rats	B-OG
immunized	O
with	O
MOG	B-GP
1	O
-	O
125	O
in	O
IFA	O
(	O
n	O
=	O
4	O
)	O
or	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
(	O
n	O
=	O
4	O
)	O
on	O
day	O
12	O
p	O
.	O
i	O
.	O

Increased	O
Cxcr4	B-GP
and	O
Cxcl12	B-GP
expression	O
was	O
observed	O
in	O
spinal	O
cord	O
of	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
CFA	O
and	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
001	O
).	O

There	O
was	O
an	O
upregulation	O
of	O
Cxcr4	B-GP
and	O
Cxcl12	B-GP
mRNA	O
in	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
compared	O
to	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
immunized	O
with	O
CFA	O
alone	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
01	O
).	O

Quantitative	O
PCR	O
results	O
are	O
expressed	O
as	O
2	O
−	O
ΔΔCT	O
values	O
.	O

Numbers	O
are	O
mean	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O

Cxcr4	B-GP
and	O
CXCL12	B-GP
in	O
individuals	O
with	O
MS	B-DS

Upregulation	O
of	O
CXCR4	B-GP
mRNA	O
was	O
also	O
observed	O
in	O
white	O
blood	O
cells	O
of	O
individuals	O
with	O
MS	B-DS
with	O
a	O
relapsing	O
-	O
remitting	O
disease	O
course	O
(	O
RRMS	O
;	O
n	O
=	O
32	O
)	O
and	O
a	O
secondary	O
chronic	B-DS
progressive	I-DS
disease	I-DS
course	O
(	O
SPMS	O
;	O
n	O
=	O
22	O
),	O
and	O
compared	O
to	O
controls	O
(	O
n	O
=	O
25	O
,	O
ANOVA	O
,	O
RRMS	O
and	O
SPMS	O
each	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
3A	O
,	O
Tables	O
S6	O
and	O
S7	O
).	O

Also	O
,	O
we	O
detected	O
increased	O
protein	O
CXCL12	B-GP
serum	O
levels	O
in	O
both	O
individuals	O
with	O
RRMS	O
(	O
n	O
=	O
24	O
)	O
and	O
SPMS	O
(	O
n	O
=	O
28	O
)	O
compared	O
to	O
controls	O
(	O
n	O
=	O
21	O
,	O
ANOVA	O
,	O
RRMS	O
and	O
SPMS	O
each	O
P	O
<	O
0	O
.	O
05	O
)	O
(	O
Fig	O
.	O
3B	O
,	O
Tables	O
S6	O
and	O
S7	O
).	O
Fig	O
.	O
3	O
.	O
Cxcr4	B-GP
expression	O
in	O
white	O
blood	O
cells	O
and	O
CXCL12	B-GP
protein	O
in	O
serum	O
of	O
individuals	O
with	O
MS	B-DS
.	O
(	O
A	O
)	O
Cxcr4	B-GP
mRNA	O
was	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
from	O
white	O
blood	O
cells	O
of	O
individuals	O
with	O
relapsing	B-DS
-	I-DS
remitting	I-DS
MS	I-DS
(	O
RR	B-DS
-	I-DS
MS	I-DS
;	O
gray	O
bars	O
,	O
n	O
=	O
32	O
),	O
secondary	B-DS
chronic	I-DS
-	I-DS
progressive	I-DS
MS	I-DS
(	O
SP	B-DS
-	I-DS
MS	I-DS
;	O
black	O
bars	O
,	O
n	O
=	O
22	O
)	O
and	O
controls	O
(	O
white	O
bars	O
,	O
n	O
=	O
25	O
).	O

Upregulation	O
of	O
Cxcr4	B-GP
in	O
both	O
patient	O
groups	O
compared	O
to	O
controls	O
was	O
observed	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
).	O

(	O
B	O
)	O
CXCL12	B-GP
serum	O
levels	O
were	O
assessed	O
by	O
ELISA	O
in	O
individuals	O
with	O
RR	B-DS
-	I-DS
MS	I-DS
(	O
gray	O
bars	O
,	O
n	O
=	O
24	O
),	O
SP	B-DS
-	I-DS
MS	I-DS
(	O
black	O
bars	O
,	O
n	O
=	O
28	O
)	O
and	O
controls	O
(	O
white	O
bars	O
,	O
n	O
=	O
21	O
).	O

Increased	O
serum	O
levels	O
of	O
CXCL12	B-GP
were	O
measured	O
in	O
both	O
MS	B-DS
groups	O
compared	O
to	O
controls	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
).	O

Quantitative	O
PCR	O
results	O
are	O
expressed	O
as	O
2	O
−	O
ΔΔCT	O
values	O
.	O

Numbers	O
are	O
mean	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O

EAE	B-DS
in	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
mice	B-OG

Cd38	B-GP
was	O
strongly	O
upregulated	O
in	O
encephalitogenic	O
LN	O
cells	O
.	O

To	O
functionally	O
validate	O
our	O
data	O
and	O
to	O
elucidate	O
the	O
role	O
of	O
CD38	B-GP
in	O
EAE	B-DS
,	O
we	O
induced	O
disease	O
with	O
the	O
extracellular	O
domain	O
of	O
MOG	B-GP
(	O
MOG	B-GP
1	O
-	O
125	O
)	O
in	O
Cd38	B-GP
-	O
knockout	O
(	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
)	O
mice	B-OG
and	O
appropriate	O
controls	O
.	O

We	O
found	O
reduced	O
disease	O
severity	O
in	O
MOG	B-GP
1	O
-	O
125	O
-	O
immunized	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
mice	B-OG
(	O
n	O
=	O
22	O
)	O
compared	O
to	O
wild	O
-	O
type	O
control	O
mice	B-OG
(	O
n	O
=	O
21	O
,	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Fig	O
.	O
4A	O
).	O

Next	O
,	O
we	O
determined	O
the	O
height	O
of	O
the	O
antibody	B-GP
response	O
to	O
MOG	B-GP
1	O
-	O
125	O
.	O

Reduced	O
anti	O
-	O
MOG	B-GP
IgG	B-GP
autoantibody	B-GP
responses	O
in	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
mice	B-OG
(	O
n	O
=	O
4	O
)	O
compared	O
to	O
wild	O
-	O
type	O
control	O
mice	B-OG
(	O
n	O
=	O
4	O
,	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
after	O
immunization	O
with	O
MOG	B-GP
1	O
-	O
125	O
were	O
seen	O
(	O
Fig	O
.	O
4B	O
)	O
on	O
day	O
12	O
post	O
-	O
immunization	O
(	O
p	O
.	O
i	O
.).	O

Furthermore	O
,	O
also	O
T	O
-	O
cell	O
responses	O
upon	O
restimulation	O
with	O
MOG	B-GP
1	O
-	O
125	O
were	O
reduced	O
in	O
the	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
mice	B-OG
(	O
n	O
=	O
4	O
)	O
on	O
day	O
12	O
p	O
.	O
i	O
.	O
compared	O
to	O
control	O
mice	B-OG
(	O
n	O
=	O
4	O
,	O
t	O
-	O
test	O
for	O
stimulation	O
with	O
50	O
µg	O
/	O
ml	O
MOG	B-GP
1	O
-	O
125	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
as	O
measured	O
in	O
a	O
proliferation	O
assay	O
,	O
indicating	O
in	O
addition	O
a	O
T	O
-	O
cell	O
priming	O
or	O
expansion	O
defect	O
in	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
mice	B-OG
(	O
Fig	O
.	O
4C	O
).	O
Fig	O
.	O
4	O
.	O
EAE	B-DS
in	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
mice	B-OG
.	O
(	O
A	O
)	O
EAE	B-DS
was	O
induced	O
in	O
female	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
mice	B-OG
(	O
white	O
triangles	O
)	O
and	O
C57BL	O
/	O
6J	O
000664	O
controls	O
(	O
black	O
triangles	O
)	O
with	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
.	O

On	O
days	O
0	O
and	O
2	O
p	O
.	O
i	O
.,	O
mice	B-OG
received	O
an	O
intravenous	O
injection	O
of	O
150	O
ng	O
pertussis	B-GP
toxin	I-GP
.	O

EAE	B-DS
was	O
scored	O
as	O
follows	O
:	O
0	O
,	O
no	O
disease	O
;	O
1	O
,	O
tail	O
paralysis	O
;	O
2	O
,	O
paraparesis	O
;	O
3	O
,	O
paraplegia	B-DS
;	O
4	O
,	O
tetraparalysis	O
;	O
5	O
,	O
moribund	O
or	O
dead	O
.	O

Immunization	O
with	O
the	O
extracellular	O
domain	O
of	O
MOG	B-GP
1	O
-	O
125	O
resulted	O
in	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
mice	B-OG
(	O
n	O
=	O
22	O
)	O
with	O
lower	O
disease	O
severity	O
compared	O
to	O
C57BL	B-OG
/	I-OG
6J	I-OG
000664	I-OG
mice	I-OG
(	O
n	O
=	O
21	O
)	O
(	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
,	O
P	O
=	O
0	O
.	O
01	O
).	O

(	O
B	O
)	O
Antibodies	B-GP
against	O
MOG	B-GP
1	O
-	O
125	O
were	O
measured	O
by	O
ELISA	O
as	O
described	O
(	O
Weissert	O
et	O
al	O
.,	O
2001	O
).	O

B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
mice	B-OG
(	O
white	O
bars	O
,	O
n	O
=	O
4	O
)	O
had	O
reduced	O
IgG	B-GP
and	O
IgG1	B-GP
antibodies	B-GP
compared	O
to	O
C57BL	O
/	O
6J	O
000664	O
mice	B-OG
(	O
black	O
bars	O
,	O
n	O
=	O
4	O
)	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
)	O
on	O
day	O
12	O
p	O
.	O
i	O
.	O

(	O
C	O
)	O
T	O
-	O
cell	O
responses	O
upon	O
restimulation	O
against	O
MOG	B-GP
1	O
-	O
125	O
from	O
draining	O
lymph	O
nodes	O
(	O
LNs	O
)	O
on	O
day	O
12	O
p	O
.	O
i	O
.	O
were	O
reduced	O
in	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
(	O
white	O
triangles	O
,	O
n	O
=	O
4	O
)	O
compared	O
to	O
C57BL	O
/	O
6J	O
000664	O
(	O
black	O
triangles	O
,	O
n	O
=	O
4	O
)	O
mice	B-OG
(	O
t	O
-	O
test	O
for	O
stimulation	O
with	O
50	O
µg	O
/	O
ml	O
MOG	B-GP
1	O
-	O
125	O
,	O
*	O
P	O
=	O
0	O
.	O
05	O
).	O

Numbers	O
are	O
mean	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O

Targeting	O
cellular	O
migration	O
by	O
FTY720	O

We	O
found	O
an	O
upregulation	O
of	O
Akt	B-GP
in	O
our	O
differential	O
gene	O
expression	O
studies	O
(	O
Table	O
1	O
).	O

FTY720	O
is	O
an	O
S1P	B-GP
-	I-GP
receptor	I-GP
modulator	O
known	O
to	O
influence	O
T	O
-	O
cell	O
trafficking	O
by	O
an	O
Akt	B-GP
-	O
dependent	O
mechanism	O
,	O
as	O
does	O
CXCR4	B-GP
(	O
Mandala	O
et	O
al	O
.,	O
2002	O
;	O
Cyster	O
,	O
2005	O
;	O
Lee	O
et	O
al	O
.,	O
2001	O
;	O
Brinkmann	O
et	O
al	O
.,	O
2002	O
;	O
Matloubian	O
et	O
al	O
.,	O
2004	O
).	O

We	O
evaluated	O
inhibition	O
of	O
Akt	B-GP
-	O
dependent	O
cell	O
trafficking	O
in	O
MOG	B-GP
91	O
-	O
108	O
-	O
immunized	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
.	O

Disease	O
was	O
completely	O
inhibited	O
in	O
rats	B-OG
treated	O
from	O
day	O
0	O
p	O
.	O
i	O
.	O
with	O
FTY720	O
(	O
n	O
=	O
10	O
)	O
as	O
compared	O
to	O
the	O
vehicle	O
-	O
treated	O
controls	O
(	O
n	O
=	O
10	O
,	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
P	O
<	O
0	O
.	O
0001	O
)	O
(	O
Fig	O
.	O
5A	O
).	O

Next	O
,	O
we	O
tested	O
the	O
efficacy	O
of	O
FTY720	O
to	O
treat	O
established	O
relapsing	O
-	O
remitting	O
MOG	B-GP
1	O
-	O
125	O
-	O
induced	O
EAE	B-DS
in	O
the	O
DA	O
(	O
RT1av1	O
)	O
rat	B-OG
.	O

FTY720	O
treatment	O
was	O
started	O
on	O
day	O
21	O
p	O
.	O
i	O
.,	O
after	O
the	O
first	O
bout	O
of	O
disease	O
(	O
n	O
=	O
8	O
),	O
and	O
showed	O
a	O
significant	O
effect	O
on	O
the	O
disease	O
course	O
as	O
compared	O
to	O
vehicle	O
treatment	O
(	O
n	O
=	O
8	O
,	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
day	O
21	O
-	O
44	O
p	O
.	O
i	O
.,	O
P	O
<	O
0	O
.	O
01	O
)	O
(	O
Fig	O
.	O
5B	O
).	O

To	O
further	O
examine	O
the	O
beneficial	O
effect	O
of	O
FTY720	O
treatment	O
on	O
EAE	B-DS
,	O
we	O
boosted	O
the	O
rats	B-OG
with	O
MOG	B-GP
1	O
-	O
125	O
on	O
day	O
44	O
after	O
the	O
first	O
immunization	O
.	O

Although	O
a	O
relapse	O
was	O
induced	O
in	O
both	O
groups	O
,	O
the	O
DA	O
rats	B-OG
under	O
FTY720	O
treatment	O
had	O
a	O
better	O
clinical	O
outcome	O
compared	O
to	O
the	O
vehicle	O
-	O
treated	O
animals	B-OG
(	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
day	O
45	O
-	O
56	O
p	O
.	O
i	O
.,	O
P	O
<	O
0	O
.	O
0001	O
).	O

On	O
day	O
14	O
p	O
.	O
i	O
.,	O
FTY720	O
treatment	O
led	O
to	O
an	O
increase	O
of	O
the	O
relative	O
size	O
of	O
the	O
CD4	B-GP
T	O
-	O
cell	O
compartment	O
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
in	O
the	O
treated	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
(	O
n	O
=	O
10	O
)	O
compared	O
to	O
controls	O
(	O
n	O
=	O
9	O
)	O
concurrent	O
with	O
a	O
decrease	O
in	O
the	O
CD8	B-GP
T	O
-	O
cell	O
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
the	O
B	O
-	O
cell	O
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
compartment	O
(	O
Fig	O
.	O
5C	O
;	O
Fig	O
.	O
S1	O
).	O

FTY720	O
treatment	O
(	O
n	O
=	O
9	O
)	O
compared	O
to	O
controls	O
(	O
n	O
=	O
9	O
)	O
led	O
to	O
the	O
downregulation	O
of	O
mRNA	O
expression	O
of	O
its	O
receptor	O
,	O
S1p1	B-GP
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
0001	O
),	O
and	O
of	O
Akt2	B-GP
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
0001	O
),	O
one	O
of	O
the	O
genes	O
involved	O
in	O
the	O
intracellular	O
signaling	O
cascade	O
connected	O
to	O
S1P1	B-GP
and	O
CXCR4	B-GP
,	O
on	O
day	O
14	O
p	O
.	O
i	O
.	O

Treatment	O
also	O
had	O
a	O
negative	O
effect	O
on	O
the	O
expression	O
levels	O
of	O
Cd38	B-GP
(	O
ANOVA	O
,	O
P	O
<	O
0	O
.	O
0001	O
).	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
Cxcr4	B-GP
was	O
not	O
altered	O
(	O
ANOVA	O
,	O
not	O
significant	O
)	O
(	O
Fig	O
.	O
5D	O
).	O
Fig	O
.	O
5	O
.	O
Influence	O
of	O
FTY720	O
in	O
EAE	B-DS
.	O
(	O
A	O
)	O
Female	O
LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
were	O
immunized	O
with	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
.	O

EAE	B-DS
was	O
scored	O
as	O
follows	O
:	O
0	O
,	O
no	O
disease	O
;	O
1	O
,	O
tail	O
paralysis	O
;	O
2	O
,	O
paraparesis	O
;	O
3	O
,	O
paraplegia	B-DS
;	O
4	O
,	O
tetraparalysis	O
;	O
5	O
,	O
moribund	O
or	O
dead	O
.	O

FTY720	O
completely	O
inhibited	O
EAE	B-DS
in	O
rats	B-OG
treated	O
orally	O
with	O
0	O
.	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
from	O
day	O
0	O
p	O
.	O
i	O
.	O
daily	O
(	O
white	O
triangles	O
,	O
n	O
=	O
10	O
)	O
as	O
compared	O
to	O
vehicle	O
(	O
PBS	O
)-	O
treated	O
controls	O
(	O
black	O
triangles	O
,	O
n	O
=	O
10	O
)	O
(	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
,	O
P	O
<	O
0	O
.	O
0001	O
).	O

(	O
B	O
)	O
Female	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
treated	O
orally	O
with	O
0	O
.	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
FTY720	O
daily	O
starting	O
on	O
day	O
21	O
p	O
.	O
i	O
.	O
after	O
a	O
first	O
bout	O
of	O
disease	O
(	O
white	O
triangles	O
,	O
n	O
=	O
8	O
)	O
showed	O
a	O
reduced	O
disease	O
course	O
compared	O
to	O
vehicle	O
(	O
PBS	O
)-	O
treated	O
controls	O
(	O
black	O
triangles	O
,	O
n	O
=	O
8	O
)	O
(	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
day	O
21	O
-	O
44	O
p	O
.	O
i	O
.,	O
P	O
=	O
0	O
.	O
01	O
).	O

On	O
day	O
44	O
p	O
.	O
i	O
.,	O
rats	B-OG
were	O
boosted	O
with	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
.	O

Both	O
groups	O
relapsed	O
but	O
with	O
a	O
better	O
outcome	O
for	O
the	O
FTY720	O
-	O
treated	O
group	O
(	O
t	O
-	O
test	O
,	O
cumulative	O
disease	O
score	O
day	O
45	O
-	O
56	O
p	O
.	O
i	O
.,	O
P	O
<	O
0	O
.	O
0001	O
).	O

(	O
C	O
)	O
FACS	O
analysis	O
of	O
cells	O
from	O
draining	O
lymph	O
nodes	O
(	O
LNs	O
)	O
demonstrated	O
an	O
increase	O
in	O
relative	O
size	O
of	O
the	O
CD4	B-GP
T	O
-	O
cell	O
compartment	O
and	O
a	O
decrease	O
in	O
the	O
size	O
of	O
the	O
CD8	B-GP
and	O
B	O
-	O
cell	O
compartment	O
in	O
FTY720	O
-	O
treated	O
(	O
white	O
bars	O
,	O
n	O
=	O
10	O
)	O
rats	B-OG
compared	O
to	O
controls	O
(	O
black	O
bars	O
,	O
n	O
=	O
9	O
)	O
(	O
ANOVA	O
,	O
*	O
P	O
<	O
0	O
.	O
01	O
)	O
on	O
day	O
14	O
p	O
.	O
i	O
.	O

(	O
D	O
)	O
Expression	O
of	O
S1p1	B-GP
(	O
Edg1	B-GP
),	O
Akt2	B-GP
,	O
Cxcr4	B-GP
and	O
Cd38	B-GP
was	O
assessed	O
in	O
FTY720	O
-	O
treated	O
rats	B-OG
(	O
white	O
bars	O
,	O
n	O
=	O
9	O
)	O
compared	O
to	O
vehicle	O
-	O
treated	O
controls	O
(	O
black	O
bars	O
,	O
n	O
=	O
9	O
)	O
by	O
quantitative	O
PCR	O
.	O

FTY720	O
treatment	O
led	O
to	O
downregulation	O
of	O
S1p1	B-GP
and	O
Akt2	B-GP
as	O
well	O
as	O
Cd38	B-GP
,	O
but	O
not	O
of	O
Cxcr4	B-GP
(	O
ANOVA	O
for	O
all	O
except	O
Cxcr4	B-GP
,	O
*	O
P	O
<	O
0	O
.	O
0001	O
)	O
on	O
day	O
14	O
p	O
.	O
i	O
.	O
from	O
cells	O
derived	O
from	O
LNs	O
.	O

Results	O
are	O
expressed	O
as	O
2	O
−	O
ΔΔCT	O
values	O
.	O

Numbers	O
are	O
mean	O
±	O
s	O
.	O
e	O
.	O
m	O
.	O

DISCUSSION	O

In	O
this	O
study	O
we	O
identified	O
gene	O
networks	O
that	O
are	O
crucially	O
involved	O
not	O
only	O
in	O
raising	O
an	O
autoantigen	O
-	O
specific	O
immune	O
response	O
but	O
also	O
in	O
constituting	O
encephalitogenicity	O
.	O

We	O
analyzed	O
the	O
expression	O
and	O
functional	O
relevance	O
of	O
genes	O
and	O
their	O
products	O
expressed	O
on	O
lymphocytes	O
after	O
immunization	O
with	O
the	O
encephalitogenic	O
MOG	B-GP
91	O
-	O
108	O
peptide	O
in	O
adjuvant	O
,	O
the	O
non	O
-	O
encephalitogenic	O
MOG	B-GP
73	O
-	O
90	O
peptide	O
in	O
adjuvant	O
,	O
adjuvant	O
alone	O
or	O
naive	O
rats	B-OG
.	O

Most	O
interestingly	O
,	O
in	O
the	O
comparison	O
of	O
MOG	B-GP
91	O
-	O
108	O
in	O
adjuvant	O
to	O
MOG	B-GP
73	O
-	O
90	O
in	O
adjuvant	O
immunized	O
rats	B-OG
,	O
compared	O
to	O
the	O
other	O
analyses	O
,	O
only	O
a	O
small	O
number	O
of	O
genes	O
were	O
differentially	O
expressed	O
.	O

These	O
genes	O
seem	O
to	O
be	O
of	O
major	O
importance	O
because	O
they	O
are	O
genes	O
involved	O
in	O
the	O
encephalitogenic	O
response	O
leading	O
to	O
disease	O
manifestation	O
.	O

From	O
the	O
overall	O
expression	O
data	O
,	O
we	O
selected	O
three	O
genes	O
that	O
were	O
upregulated	O
in	O
many	O
comparisons	O
:	O
Cxcr4	B-GP
,	O
Cd38	B-GP
and	O
Akt	B-GP
.	O

We	O
performed	O
functional	O
studies	O
regarding	O
these	O
genes	O
in	O
EAE	B-DS
and	O
analyzed	O
tissue	O
samples	O
from	O
individuals	O
with	O
MS	B-DS
.	O

CXCR4	B-GP
(	O
CD184	B-GP
)	O
is	O
a	O
seven	B-GP
-	I-GP
transmembrane	I-GP
G	I-GP
-	I-GP
coupled	I-GP
receptor	I-GP
expressed	O
by	O
a	O
number	O
of	O
tissues	O
,	O
including	O
cells	O
of	O
the	O
immune	O
system	O
(	O
Campbell	O
et	O
al	O
.,	O
2003	O
).	O
Cxcr4	B-GP
-	O
knockout	O
mice	B-OG
die	O
in	O
utero	O
or	O
perinatally	O
and	O
do	O
not	O
only	O
have	O
defects	O
in	O
the	O
hematopoietic	O
system	O
(	O
impairment	O
of	O
myeloid	O
and	O
B	O
-	O
cell	O
generation	O
,	O
reduced	O
proliferation	O
of	O
triple	O
-	O
negative	O
and	O
double	O
-	O
positive	O
lymphocytes	O
),	O
but	O
also	O
in	O
the	O
circulatory	O
system	O
and	O
in	O
the	O
CNS	O
(	O
Zou	O
et	O
al	O
.,	O
1998	O
;	O
Tachibana	O
et	O
al	O
.,	O
1998	O
).	O

Overexpression	O
of	O
CXCR4	B-GP
on	O
T	O
cells	O
induces	O
their	O
accumulation	O
in	O
the	O
bone	O
marrow	O
and	O
reduction	O
of	O
these	O
cells	O
in	O
the	O
peripheral	O
blood	O
.	O

CXCR4	B-GP
signaling	O
leads	O
to	O
a	O
prolonged	O
protein	B-GP
kinase	I-GP
B	I-GP
(	O
AKT	B-GP
)	O
and	O
extracellular	B-GP
signal	I-GP
-	I-GP
regulated	I-GP
kinase	I-GP
2	I-GP
activation	O
in	O
T	O
cells	O
.	O

AKT	B-GP
activation	O
promotes	O
cell	O
survival	O
and	O
can	O
act	O
as	O
a	O
co	O
-	O
stimulation	O
for	O
T	O
-	O
cell	O
activation	O
(	O
Tilton	O
et	O
al	O
.,	O
2000	O
).	O

CXCR4	B-GP
has	O
only	O
one	O
known	O
cognate	O
ligand	O
,	O
which	O
is	O
CXCL12	B-GP
.	O

CXCL12	B-GP
is	O
constitutively	O
produced	O
by	O
stromal	O
and	O
endothelial	O
cells	O
.	O

CXCL12	B-GP
activates	O
numerous	O
signaling	O
pathways	O
,	O
such	O
as	O
receptor	O
-	O
associated	O
trimeric	O
G	B-GP
proteins	I-GP
,	O
phospholipase	B-GP
Cγ	I-GP
,	O
PI3K	B-GP
and	O
small	B-GP
G	I-GP
proteins	I-GP
(	O
Pawig	O
et	O
al	O
.,	O
2015	O
).	O

Signaling	O
through	O
these	O
receptors	O
leads	O
to	O
an	O
increase	O
in	O
the	O
intracellular	O
calcium	O
concentration	O
,	O
cytoskeleton	O
reorganization	O
and	O
cellular	O
migration	O
.	O

Several	O
modulating	O
factors	O
such	O
as	O
phosphatases	B-GP
,	O
regulator	B-GP
of	I-GP
G	I-GP
-	I-GP
protein	I-GP
signaling	I-GP
,	O
adaptor	B-GP
proteins	I-GP
and	O
ubiquitin	B-GP
may	O
affect	O
signaling	O
and	O
/	O
or	O
chemotactic	O
response	O
of	O
CXCR4	B-GP
to	O
its	O
ligand	O
(	O
CXCL12	B-GP
).	O

An	O
important	O
function	O
of	O
CXCR4	B-GP
/	O
CXCL12	B-GP
is	O
the	O
regulation	O
of	O
bone	O
-	O
marrow	O
homeostasis	O
and	O
lymphocyte	O
trafficking	O
.	O

Chemotaxis	O
and	O
integrin	B-GP
-	O
mediated	O
adhesion	O
are	O
the	O
main	O
cellular	O
responses	O
to	O
CXCL12	B-GP
.	O
Cxcl12	B-GP
-	O
knockout	O
mice	B-OG
display	O
the	O
same	O
phenotype	O
as	O
Cxcr4	B-GP
-	O
knockout	O
mice	B-OG
(	O
Nagasawa	O
et	O
al	O
.,	O
1996	O
).	O

In	O
autoimmunity	O
there	O
are	O
indications	O
that	O
the	O
interaction	O
of	O
CXCR4	B-GP
and	O
CXCL12	B-GP
could	O
be	O
important	O
.	O

CXCL12	B-GP
recruits	O
B	O
cells	O
to	O
inflamed	O
glomeruli	O
,	O
in	O
which	O
these	O
cells	O
can	O
produce	O
autoantibodies	B-GP
(	O
Balabanian	O
et	O
al	O
.,	O
2003	O
).	O

Also	O
,	O
in	O
rheumatoid	B-DS
arthritis	I-DS
,	O
CXCR4	B-GP
and	O
CXCL12	B-GP
have	O
been	O
proposed	O
to	O
be	O
important	O
in	O
the	O
disease	O
precipitation	O
(	O
Zhang	O
et	O
al	O
.,	O
2005	O
).	O

A	O
role	O
of	O
CXCR4	B-GP
and	O
CXCL12	B-GP
in	O
EAE	B-DS
(	O
Meiron	O
et	O
al	O
.,	O
2008	O
;	O
Kohler	O
et	O
al	O
.,	O
2008	O
;	O
McCandless	O
et	O
al	O
.,	O
2006	O
)	O
as	O
well	O
as	O
in	O
MS	B-DS
(	O
Azin	O
et	O
al	O
.,	O
2012	O
;	O
Krumbholz	O
et	O
al	O
.,	O
2006	O
)	O
has	O
been	O
described	O
.	O

Our	O
data	O
indicate	O
that	O
,	O
also	O
in	O
MOG	B-GP
-	O
induced	O
EAE	B-DS
and	O
possibly	O
in	O
MS	B-DS
,	O
the	O
interaction	O
of	O
CXCR4	B-GP
and	O
CXCL12	B-GP
is	O
of	O
paramount	O
importance	O
for	O
disease	O
development	O
.	O

We	O
found	O
specific	O
upregulation	O
of	O
Cxcr4	B-GP
on	O
cells	O
derived	O
from	O
LNs	O
and	O
eluted	O
from	O
the	O
CNS	O
of	O
rats	B-OG
immunized	O
with	O
encephalitogenic	O
MOG	B-GP
91	O
-	O
108	O
peptide	O
in	O
comparison	O
to	O
controls	O
.	O

In	O
addition	O
,	O
we	O
measured	O
upregulation	O
of	O
Cxcl12	B-GP
and	O
Cxcr4	B-GP
in	O
spinal	O
cords	O
in	O
EAE	B-DS
rats	B-OG
compared	O
to	O
controls	O
.	O

CXCL12	B-GP
is	O
upregulated	O
in	O
the	O
CNS	O
of	O
individuals	O
with	O
MS	B-DS
(	O
Krumbholz	O
et	O
al	O
.,	O
2006	O
and	O
our	O
own	O
unpublished	O
observations	O
).	O

Together	O
,	O
the	O
presented	O
data	O
would	O
argue	O
for	O
a	O
scenario	O
in	O
which	O
LN	O
-	O
derived	O
cells	O
are	O
,	O
in	O
the	O
context	O
of	O
an	O
encounter	O
with	O
an	O
encephalitogenic	O
antigen	O
,	O
activated	O
and	O
migrate	O
towards	O
CXCL12	B-GP
in	O
the	O
CNS	O
.	O

This	O
is	O
further	O
underscored	O
by	O
the	O
fact	O
that	O
nitric	O
oxide	O
enhances	O
lipopolysaccharide	O
(	O
LPS	O
)-	O
induced	O
expression	O
of	O
CXCR4	B-GP
and	O
migration	O
towards	O
CXCL12	B-GP
(	O
Giordano	O
et	O
al	O
.,	O
2006	O
).	O

CD38	B-GP
is	O
a	O
membrane	B-GP
-	I-GP
associated	I-GP
type	I-GP
II	I-GP
glycoprotein	I-GP
that	O
acts	O
both	O
as	O
a	O
receptor	O
and	O
enzyme	O
(	O
Cockayne	O
et	O
al	O
.,	O
1998	O
;	O
Kato	O
et	O
al	O
.,	O
1999	O
;	O
Salmi	O
and	O
Jalkanen	O
,	O
2005	O
).	O

As	O
an	O
enzyme	O
it	O
catalyzes	O
NAD	O
+	O
into	O
cyclic	O
ADP	O
-	O
ribose	O
and	O
further	O
into	O
ADP	O
-	O
ribose	O
.	O

It	O
also	O
regulates	O
Ca2	O
+	O
levels	O
from	O
ryanodine	B-GP
receptor	I-GP
stores	O
.	O

CD38	B-GP
is	O
expressed	O
on	O
a	O
variety	O
of	O
myeloid	O
and	O
lymphoid	O
cells	O
.	O

CD38	B-GP
ligation	O
in	O
B	O
cells	O
leads	O
to	O
tyrosine	O
phosphorylation	O
of	O
several	O
intracellular	O
proteins	O
such	O
as	O
Syk	B-GP
,	O
p85	B-GP
of	O
phophatidylinositol	B-GP
-	I-GP
3	I-GP
kinase	I-GP
and	O
phospholipase	B-GP
C	I-GP
-	I-GP
γ	I-GP
(	O
Silvennoinen	O
et	O
al	O
.,	O
1996	O
).	O

CD38	B-GP
ligation	O
in	O
T	O
cells	O
results	O
in	O
phosphorylation	O
of	O
the	O
Raf	B-GP
-	I-GP
1	I-GP
/	O
MAP	B-GP
kinase	I-GP
and	O
CD3	B-GP
-	I-GP
ζ	I-GP
/	O
ZAP	B-GP
-	I-GP
70	I-GP
signaling	O
pathway	O
(	O
Zubiaur	O
et	O
al	O
.,	O
1997	O
).	O

Furthermore	O
,	O
it	O
is	O
involved	O
in	O
dendritic	O
cell	O
migration	O
and	O
adhesion	O
between	O
lymphocytes	O
and	O
endothelial	O
cells	O
(	O
Partida	O
-	O
Sanchez	O
et	O
al	O
.,	O
2004	O
).	O

B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
mice	B-OG
show	O
a	O
slight	O
reduction	O
of	O
antibody	B-GP
titers	O
to	O
T	O
-	O
cell	O
-	O
dependent	O
antigens	O
(	O
Cockayne	O
et	O
al	O
.,	O
1998	O
).	O

Additionally	O
,	O
these	O
mice	B-OG
had	O
increased	O
susceptibility	O
to	O
bacterial	B-DS
infections	I-DS
,	O
which	O
is	O
thought	O
to	O
be	O
caused	O
by	O
a	O
defective	O
chemotactic	O
response	O
of	O
neutrophils	O
towards	O
bacteria	O
,	O
underscoring	O
a	O
role	O
in	O
innate	O
immunity	O
as	O
well	O
(	O
Partida	O
-	O
Sanchez	O
et	O
al	O
.,	O
2001	O
).	O

We	O
induced	O
EAE	B-DS
in	O
Cd38	B-GP
-	O
knockout	O
mice	B-OG
(	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
)	O
and	O
controls	O
.	O
Cd38	B-GP
-	O
knockout	O
mice	B-OG
had	O
a	O
reduced	O
disease	O
severity	O
and	O
lower	O
autoantibody	B-GP
and	O
T	O
-	O
cell	O
responses	O
as	O
compared	O
to	O
the	O
controls	O
.	O

These	O
findings	O
show	O
the	O
importance	O
of	O
CD38	B-GP
in	O
EAE	B-DS
and	O
possibly	O
MS	B-DS
.	O

This	O
work	O
forms	O
the	O
basis	O
for	O
further	O
analysis	O
of	O
the	O
involved	O
cellular	O
compartments	O
and	O
regulation	O
of	O
human	B-OG
disease	O
(	O
Mayo	O
et	O
al	O
.,	O
2008	O
;	O
Lischke	O
et	O
al	O
.,	O
2013	O
).	O

FTY720	O
is	O
a	O
potent	O
drug	O
that	O
affects	O
lymphocyte	O
trafficking	O
and	O
homing	O
.	O

Our	O
studies	O
and	O
studies	O
by	O
others	O
(	O
Brinkmann	O
et	O
al	O
.,	O
2002	O
;	O
Balatoni	O
et	O
al	O
.,	O
2007	O
)	O
showed	O
a	O
strong	O
beneficial	O
effect	O
of	O
FTY720	O
on	O
EAE	B-DS
under	O
various	O
experimental	O
settings	O
.	O

The	O
drug	O
was	O
approved	O
for	O
treatment	O
of	O
MS	B-DS
(	O
Kappos	O
et	O
al	O
.,	O
2010	O
).	O

We	O
demonstrate	O
that	O
treatment	O
of	O
MOG	B-GP
-	O
induced	O
EAE	B-DS
with	O
FTY720	O
impacts	O
the	O
gene	O
expression	O
of	O
the	O
genes	O
that	O
are	O
involved	O
in	O
encephalitogenic	O
immune	O
responses	O
.	O

This	O
further	O
validates	O
our	O
approach	O
.	O

We	O
measured	O
changes	O
in	O
expression	O
of	O
S1P1	B-GP
,	O
Akt2	B-GP
and	O
Cd38	B-GP
.	O

Interestingly	O
,	O
no	O
changes	O
in	O
expression	O
of	O
Cxcr4	B-GP
was	O
observed	O
.	O

The	O
reason	O
for	O
this	O
is	O
not	O
fully	O
understood	O
and	O
deserves	O
further	O
investigations	O
.	O

In	O
conclusion	O
,	O
in	O
this	O
study	O
we	O
have	O
identified	O
genes	O
that	O
are	O
involved	O
not	O
only	O
in	O
raising	O
autoantigen	O
-	O
specific	O
immune	O
responses	O
but	O
which	O
constitute	O
encephalitogenicity	O
.	O

The	O
immunization	O
with	O
encephalitogenic	O
peptides	O
induces	O
a	O
network	O
of	O
genes	O
involved	O
in	O
activation	O
and	O
migration	O
of	O
lymphocytes	O
.	O

Based	O
on	O
this	O
platform	O
,	O
we	O
have	O
established	O
the	O
paramount	O
importance	O
of	O
G	B-GP
-	I-GP
coupled	I-GP
proteins	I-GP
in	O
encephalitogenicity	O
of	O
adaptive	O
immune	O
responses	O
.	O

We	O
speculate	O
that	O
similar	O
involvement	O
might	O
operate	O
also	O
in	O
other	O
autoimmune	B-DS
diseases	I-DS
and	O
possibly	O
in	O
transplant	O
rejection	O
,	O
thereby	O
establishing	O
common	O
mechanisms	O
.	O

These	O
pathways	O
might	O
be	O
valuable	O
targets	O
of	O
therapeutic	O
approaches	O
as	O
we	O
have	O
shown	O
attenuation	O
of	O
EAE	B-DS
after	O
treatment	O
with	O
FTY720	O
or	O
reduced	O
EAE	B-DS
severity	O
in	O
CD38	B-GP
-	O
deficient	O
mice	B-OG
.	O

These	O
findings	O
not	O
only	O
validate	O
our	O
gene	O
expression	O
data	O
,	O
but	O
also	O
underscore	O
the	O
importance	O
of	O
the	O
rat	B-OG
EAE	B-DS
model	O
in	O
translational	O
medicine	O
.	O

MATERIALS	O
AND	O
METHODS	O

Animals	B-OG
and	O
EAE	B-DS
induction	O

Female	O
rats	B-OG
or	O
mice	B-OG
,	O
10	O
-	O
14	O
weeks	O
of	O
age	O
,	O
were	O
used	O
in	O
all	O
experiments	O
.	O

LEW	O
.	O
1AV1	O
(	O
RT1av1	O
)	O
rats	B-OG
were	O
obtained	O
from	O
Hans	O
Hedrich	O
(	O
Central	O
Animal	B-OG
Laboratory	O
,	O
Hannover	O
Medical	O
School	O
,	O
Hannover	O
,	O
Germany	O
)	O
and	O
DA	O
(	O
RT1av1	O
)	O
rats	B-OG
were	O
obtained	O
from	O
Harlan	O
Winkelmann	O
(	O
Borchen	O
,	O
Germany	O
).	O

Female	O
B6	O
.	O
129P2	O
-	O
Cd38tm1Lnd	O
/	O
J	O
mice	B-OG
and	O
the	O
appropriate	O
controls	O
(	O
C57BL	O
/	O
6J	O
000664	O
)	O
were	O
purchased	O
from	O
the	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
USA	O
).	O

Animals	B-OG
were	O
bred	O
and	O
kept	O
under	O
specific	O
pathogen	O
-	O
free	O
conditions	O
.	O

Animals	B-OG
were	O
injected	O
intradermally	O
at	O
the	O
base	O
of	O
the	O
tail	O
(	O
rats	B-OG
)	O
or	O
both	O
flanks	O
(	O
mice	B-OG
)	O
with	O
100	O
µg	O
of	O
MOG	B-GP
91	O
-	O
108	O
(	O
rats	B-OG
)	O
or	O
50	O
µg	O
of	O
rat	B-OG
recombinant	O
MOG	B-GP
1	O
-	O
125	O
(	O
rats	B-OG
)	O
or	O
100	O
µg	O
MOG	B-GP
35	O
-	O
55	O
(	O
mice	B-OG
)	O
or	O
20	O
µg	O
rat	B-OG
recombinant	O
MOG	B-GP
1	O
-	O
125	O
(	O
mice	B-OG
).	O

The	O
antigens	O
in	O
a	O
total	O
volume	O
of	O
100	O
µl	O
were	O
mixed	O
with	O
100	O
µl	O
of	O
CFA	O
(	O
1	O
:	O
1	O
).	O

A	O
total	O
of	O
100	O
µl	O
of	O
CFA	O
consisted	O
of	O
IFA	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
)	O
and	O
500	O
µg	O
for	O
rats	B-OG
or	O
400	O
µg	O
for	O
mice	B-OG
of	O
heat	O
-	O
inactivated	O
Mycobacterium	B-OG
tuberculosis	I-OG
(	O
strain	O
H37	O
RA	O
;	O
Difco	O
Laboratories	O
,	O
Detroit	O
,	O
MI	O
)	O
(	O
Weissert	O
,	O
2016	O
).	O

Mice	B-OG
additionally	O
received	O
100	O
ng	O
of	O
pertussis	B-GP
toxin	I-GP
(	O
Calbiochem	O
,	O
Darmstadt	O
,	O
Germany	O
)	O
on	O
day	O
0	O
and	O
2	O
intravenously	O
.	O

Some	O
groups	O
of	O
rats	B-OG
were	O
also	O
injected	O
with	O
100	O
µl	O
IFA	O
mixed	O
with	O
100	O
µl	O
MOG	B-GP
1	O
-	O
125	O
in	O
PBS	O
(	O
50	O
µg	O
)	O
without	O
the	O
addition	O
of	O
Mycobacterium	B-OG
tuberculosis	I-OG
or	O
with	O
IFA	O
or	O
CFA	O
alone	O
.	O

The	O
clinical	O
scoring	O
was	O
as	O
follows	O
:	O
0	O
=	O
no	O
illness	O
;	O
1	O
=	O
tail	O
weakness	O
or	O
paralysis	O
;	O
2	O
=	O
hind	O
-	O
leg	O
paraparesis	O
or	O
hemiparesis	O
;	O
3	O
=	O
hind	O
-	O
leg	O
paralysis	O
or	O
hemiparalysis	O
;	O
4	O
=	O
tetraparesis	O
or	O
moribund	O
.	O

All	O
experiments	O
were	O
approved	O
by	O
the	O
regional	O
board	O
in	O
Tübingen	O
,	O
Germany	O
.	O

Human	B-OG
samples	O

Blood	O
samples	O
were	O
obtained	O
after	O
consent	O
from	O
individuals	O
with	O
MS	B-DS
and	O
controls	O
.	O

The	O
characteristics	O
of	O
the	O
MS	B-DS
individuals	O
and	O
controls	O
are	O
indicated	O
in	O
Tables	O
S6	O
and	O
S7	O
.	O

The	O
research	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
University	O
of	O
Tübingen	O
in	O
Germany	O
(	O
Permission	O
125	O
/	O
2001	O
).	O

Isolation	O
of	O
CNS	O
-	O
infiltrating	O
cells	O

Infiltrating	O
cells	O
from	O
the	O
CNS	O
were	O
prepared	O
as	O
described	O
before	O
(	O
Weissert	O
et	O
al	O
.,	O
1998a	O
,	O
2001	O
).	O

In	O
brief	O
,	O
rats	B-OG
were	O
perfused	O
with	O
cold	O
PBS	O
,	O
and	O
brains	O
and	O
spinal	O
cords	O
were	O
dissected	O
out	O
on	O
day	O
12	O
p	O
.	O
i	O
.	O

Subsequently	O
,	O
brains	O
and	O
spinal	O
cords	O
were	O
homogenized	O
in	O
10	O
ml	O
50	O
%	O
Percoll	O
/	O
0	O
.	O
1	O
%	O
BSA	B-GP
/	O
1	O
%	O
glucose	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
)	O
containing	O
500	O
U	O
DNase	B-GP
type	I-GP
I	I-GP
(	O
Life	O
Technologies	O
).	O

Ten	O
ml	O
of	O
50	O
%	O
Percoll	O
was	O
added	O
to	O
each	O
sample	O
after	O
homogenization	O
.	O

A	O
discontinuous	O
Percoll	O
gradient	O
was	O
obtained	O
by	O
adding	O
7	O
ml	O
of	O
63	O
%	O
Percoll	O
below	O
and	O
20	O
ml	O
of	O
30	O
%	O
Percoll	O
above	O
the	O
sample	O
.	O

Samples	O
were	O
centrifuged	O
for	O
40	O
min	O
at	O
1000	O
g	O
at	O
4	O
°	O
C	O
.	O

Lymphocytes	O
were	O
collected	O
from	O
the	O
63	O
/	O
50	O
%	O
Percoll	O
interface	O
.	O

The	O
cells	O
were	O
subsequently	O
washed	O
twice	O
in	O
15	O
-	O
25	O
ml	O
PBS	O
with	O
centrifugation	O
at	O
600	O
g	O
for	O
15	O
min	O
at	O
4	O
°	O
C	O
.	O

Isolation	O
of	O
mononuclear	O
cells	O
from	O
lymph	O
nodes	O
and	O
spleens	O

Draining	O
inguinal	O
LNs	O
and	O
spleens	O
were	O
dissected	O
out	O
under	O
deep	O
anesthesia	O
.	O

LNs	O
were	O
disrupted	O
and	O
mononuclear	O
cells	O
(	O
MNCs	O
)	O
washed	O
twice	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
DMEM	O
;	O
Life	O
Technologies	O
,	O
Paisley	O
,	O
UK	O
),	O
resuspended	O
in	O
complete	O
medium	O
(	O
CM	O
)	O
containing	O
DMEM	O
supplemented	O
with	O
5	O
%	O
fetal	O
calf	O
serum	O
(	O
PAA	O
Laboratories	O
Linz	O
,	O
Austria	O
),	O
1	O
%	O
penicillin	O
/	O
streptomycin	O
(	O
Life	O
Technologies	O
),	O
1	O
%	O
glutamine	O
(	O
Life	O
Technologies	O
)	O
and	O
50	O
µM	O
2	O
-	O
mercaptoethanol	O
(	O
Life	O
Technologies	O
),	O
and	O
flushed	O
through	O
a	O
70	O
-	O
µm	O
plastic	O
strainer	O
(	O
Falcon	O
;	O
BD	O
Biosciences	O
,	O
Franklin	O
Lakes	O
,	O
NJ	O
).	O

MNCs	O
from	O
spleen	O
were	O
prepared	O
in	O
the	O
same	O
way	O
as	O
from	O
LNs	O
with	O
the	O
difference	O
that	O
red	O
blood	O
cells	O
were	O
lysed	O
with	O
lysis	O
buffer	O
consisting	O
of	O
0	O
.	O
15	O
M	O
NH4Cl	O
,	O
10	O
mM	O
KHCO3	O
and	O
0	O
.	O
1	O
mM	O
Na2	O
EDTA	O
adjusted	O
to	O
pH	O
7	O
.	O
4	O
.	O

CD4	B-GP
+	O
cells	O
were	O
isolated	O
by	O
anti	O
-	O
rat	B-OG
CD4	B-GP
microbeads	O
using	O
MACS	O
technology	O
(	O
Miltenyi	O
Biotech	O
,	O
Bergisch	O
Gladbach	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

CD4	B-GP
+	O
cell	O
purification	O

CD4	B-GP
+	O
cells	O
from	O
the	O
LNs	O
were	O
purified	O
by	O
MACS	O
(	O
Miltenyi	O
Biotech	O
,	O
Bergisch	O
Gladbach	O
,	O
Germany	O
)	O
and	O
subsequently	O
analyzed	O
by	O
Affymetrix	O
gene	O
array	O
for	O
differential	O
gene	O
expression	O
.	O

Spinal	O
cord	O
tissue	O

From	O
PBS	O
-	O
perfused	O
naive	O
rats	B-OG
or	O
in	O
DA	O
rats	B-OG
immunized	O
with	O
either	O
IFA	O
,	O
CFA	O
,	O
MOG	B-GP
1	O
-	O
125	O
in	O
IFA	O
or	O
MOG	B-GP
1	O
-	O
125	O
in	O
CFA	O
,	O
spinal	O
cord	O
tissue	O
was	O
dissected	O
and	O
homogenized	O
and	O
subsequently	O
assessed	O
for	O
mRNA	O
expression	O
.	O

RNA	O
preparation	O

Total	O
RNA	O
of	O
brain	O
-	O
infiltrating	O
leukocytes	O
or	O
lymphocytes	O
or	O
spinal	O
cord	O
tissue	O
was	O
isolated	O
by	O
using	O
an	O
RNeasy	O
kit	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
RNA	O
quality	O
was	O
analyzed	O
with	O
a	O
Bioanalyser	O
2100	O
(	O
Agilent	O
,	O
Palo	O
Alto	O
,	O
CA	O
).	O

Microarrays	O

Affymetrix	O
microarrays	O
of	O
the	O
type	O
RG	O
U34	O
A	O
(	O
Affymetrix	O
Inc	O
.,	O
Santa	O
Clara	O
,	O
CA	O
)	O
representing	O
approximately	O
7000	O
full	O
-	O
length	O
genes	O
and	O
1000	O
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
clusters	O
were	O
used	O
.	O

For	O
the	O
purified	O
CD4	B-GP
+	O
cells	O
,	O
the	O
rat	B-OG
expression	O
set	O
230A	O
(	O
Affymetrix	O
)	O
containing	O
about	O
30	O
,	O
000	O
features	O
was	O
used	O
.	O

For	O
each	O
array	O
,	O
samples	O
from	O
at	O
least	O
three	O
rats	B-OG
were	O
pooled	O
.	O

Biotin	O
-	O
labeled	O
cRNA	O
was	O
prepared	O
and	O
hybridized	O
to	O
the	O
arrays	O
.	O

In	O
brief	O
,	O
double	O
-	O
stranded	O
cDNA	O
was	O
synthesized	O
from	O
whole	O
RNA	O
using	O
a	O
superscript	O
choice	O
kit	O
(	O
Invitrogen	O
)	O
with	O
a	O
T7	B-OG
-(	O
dT	O
)	O
24	O
primer	O
(	O
Metabion	O
)	O
and	O
in	O
vitro	O
transcribed	O
into	O
biotin	O
-	O
labeled	O
cRNA	O
.	O

After	O
hybridization	O
,	O
gene	O
arrays	O
were	O
washed	O
and	O
stained	O
by	O
a	O
fluidics	O
station	O
(	O
Affymetrix	O
)	O
and	O
scanned	O
by	O
a	O
confocal	O
laser	O
scanning	O
microscope	O
(	O
Agilent	O
).	O

The	O
data	O
were	O
analyzed	O
using	O
the	O
microarray	O
suite	O
software	O
,	O
micro	O
DB	O
,	O
and	O
data	O
-	O
mining	O
tool	O
(	O
Affymetrix	O
).	O

Only	O
genes	O
and	O
ESTs	O
that	O
were	O
‘	O
present	O
’	O
and	O
gave	O
a	O
difference	O
call	O
of	O
either	O
‘	O
increase	O
’	O
or	O
‘	O
decrease	O
’	O
according	O
to	O
the	O
Affymetrix	O
software	O
were	O
included	O
in	O
further	O
analysis	O
.	O

The	O
extent	O
of	O
differential	O
expression	O
is	O
expressed	O
as	O
an	O
SLR	O
.	O

For	O
the	O
tables	O
,	O
the	O
cut	O
-	O
off	O
was	O
set	O
to	O
an	O
SLR	O
of	O
1	O
signifying	O
a	O
twofold	O
change	O
in	O
expression	O
.	O

Doubles	O
,	O
ESTs	O
and	O
sequences	O
not	O
corresponding	O
to	O
a	O
gene	O
were	O
not	O
included	O
in	O
the	O
tables	O
.	O

Real	O
-	O
time	O
PCR	O

To	O
avoid	O
amplification	O
/	O
detection	O
of	O
contaminating	O
genomic	O
DNA	O
,	O
extracted	O
RNA	O
was	O
treated	O
with	O
RNase	B-GP
free	O
DNase	B-GP
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
).	O

Subsequently	O
,	O
cDNA	O
was	O
synthesized	O
by	O
reverse	O
transcription	O
with	O
Moloney	B-OG
murine	I-OG
leukemia	I-OG
virus	I-OG
reverse	B-GP
transcriptase	I-GP
and	O
random	O
pdN6	O
primers	O
in	O
the	O
presence	O
of	O
RNase	B-GP
inhibitor	O
(	O
Promega	O
).	O

Amplification	O
was	O
performed	O
on	O
an	O
Applied	O
Biosystems	O
Prism	O
7000	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
using	O
a	O
SYBR	O
green	O
protocol	O
.	O

Results	O
were	O
expressed	O
as	O
2	O
−	O
ΔΔCT	O
values	O
.	O

The	O
primer	O
sequences	O
5	O
′	O
to	O
3	O
′	O
were	O
as	O
follows	O
:	O

Rat	B-OG
primers	O

forward	O
:	O
GGTTGTCTCCTGTGACTTCAA	O

reverse	O
:	O
CATACCAGGAAATGAGCTTCAC	O

forward	O
:	O
TAGCCGCAGCAAATCAGAC	O

reverse	O
:	O
GCAGCAGTGGAGAAAGAGAGA	O

forward	O
:	O
GATGGTGGTGTTCCAGTTCC	O

reverse	O
:	O
CAGCTTGGAGATGATGATGC	O

forward	O
:	O
CGATTCTTTGAGAGCCATGT	O

reverse	O
:	O
AGGGCACAGTTTGGAGTGTT	O

forward	O
:	O
AGGACACACTGCTGGGCTAT	O

reverse	O
:	O
CAGGGTTGTTGGGACAATTT	O

forward	O
:	O
GAAGACTGAGAGGCCACGAC	O

reverse	O
:	O
GGGAGCCACACTTGTAATCC	O

Human	B-OG
primers	O

forward	O
:	O
CGGCTACCACATCCAAGGAA	O

reverse	O
:	O
GCTGGAATTACCGCGGCT	O

forward	O
:	O
CATCAGTCTGGACCGCTACC	O

reverse	O
:	O
GGATCCAGACGCCAACATAG	O
.	O

FACS	O

FITC	O
-	O
conjugated	O
monoclonal	O
antibody	B-GP
(	O
mAb	O
)	O
against	O
CD45RA	B-GP
(	O
OX	O
-	O
33	O
)	O
and	O
TCRAB	B-GP
(	O
R73	O
)	O
and	O
phycoerythrin	B-GP
(	O
PE	B-GP
)-	O
conjugated	O
mAb	O
against	O
CD4	B-GP
(	O
OX	O
-	O
35	O
)	O
and	O
MHC	B-GP
II	I-GP
(	O
OX	O
-	O
6	O
)	O
and	O
appropriate	O
isotype	O
controls	O
were	O
purchased	O
from	O
Becton	O
Dickinson	O
(	O
Heidelberg	O
,	O
Germany	O
).	O

Flow	O
cytometry	O
was	O
performed	O
on	O
a	O
FACScalibur	O
running	O
with	O
Cellquest	O
software	O
(	O
Becton	O
Dickinson	O
).	O

Cells	O
were	O
gated	O
on	O
the	O
lymphocyte	O
population	O
in	O
the	O
forward	O
scatter	O
(	O
FSC	O
)-	O
side	O
scatter	O
(	O
SSC	O
)	O
dot	O
plot	O
.	O

For	O
data	O
analysis	O
,	O
Flowing	O
Software	O
2	O
.	O
5	O
.	O
1	O
(	O
Turku	O
Center	O
for	O
Biotechnology	O
,	O
Finland	O
)	O
was	O
used	O
.	O

ELISA	O

Serum	O
taken	O
at	O
the	O
time	O
point	O
of	O
euthanasia	O
was	O
subject	O
to	O
an	O
anti	O
-	O
MOG	B-GP
autoantibody	B-GP
ELISA	O
.	O

ELISA	O
plates	O
(	O
96	O
-	O
well	O
;	O
Nunc	O
,	O
Roskilde	O
,	O
Denmark	O
)	O
were	O
coated	O
with	O
2	O
.	O
5	O
µg	O
/	O
ml	O
(	O
100	O
µl	O
/	O
well	O
)	O
MOG	B-GP
1	O
-	O
125	O
overnight	O
at	O
4	O
°	O
C	O
.	O

Plates	O
were	O
washed	O
with	O
PBS	O
/	O
0	O
.	O
05	O
%	O
Tween	O
20	O
and	O
blocked	O
with	O
milk	O
powder	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

After	O
washing	O
,	O
diluted	O
serum	O
samples	O
were	O
added	O
and	O
plates	O
were	O
incubated	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Then	O
,	O
plates	O
were	O
washed	O
and	O
rabbit	B-OG
anti	O
-	O
mouse	B-OG
antiserum	O
(	O
IgG	B-GP
,	O
IgG1	B-GP
,	O
IgG2a	B-GP
,	O
IgG2b	B-GP
,	O
IgG3	B-GP
,	O
IgM	B-GP
;	O
Nordic	O
,	O
Tilburg	O
,	O
The	O
Netherlands	O
)	O
was	O
added	O
and	O
incubated	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Plates	O
were	O
washed	O
prior	O
to	O
the	O
addition	O
of	O
peroxidase	B-GP
-	O
conjugated	O
goat	B-OG
anti	O
-	O
rabbit	B-OG
antiserum	O
(	O
Nordic	O
)	O
diluted	O
in	O
PBS	O
/	O
0	O
.	O
05	O
%	O
Tween	O
20	O
.	O

After	O
30	O
min	O
incubation	O
,	O
plates	O
were	O
washed	O
and	O
bound	O
antibodies	B-GP
were	O
visualized	O
by	O
addition	O
of	O
2	O
,	O
2	O
′	O
azino	O
-	O
bis	O
(	O
3	O
-	O
ethylbenzothiazoline	O
-	O
6	O
-	O
sulphonic	O
acid	O
)	O
(	O
ABTS	O
)	O
(	O
Roche	O
Diagnostics	O
,	O
Mannheim	O
,	O
Germany	O
).	O

After	O
15	O
min	O
of	O
incubation	O
,	O
optical	O
density	O
was	O
read	O
at	O
405	O
nm	O
.	O

ELISA	O
with	O
human	B-OG
serum	O
was	O
performed	O
according	O
to	O
the	O
instructions	O
of	O
the	O
manufacturer	O
[	O
Quantikine	O
human	B-OG
SDF1alpha	B-GP
Immunoassay	O
(	O
R	O
&	O
D	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
)].	O

Proliferation	O
assay	O

Cells	O
from	O
draining	O
LNs	O
were	O
prepared	O
as	O
described	O
above	O
and	O
cultured	O
in	O
the	O
presence	O
of	O
rrMOG	B-GP
in	O
96	O
-	O
well	O
plates	O
as	O
described	O
by	O
Weissert	O
et	O
al	O
.	O
(	O
1998b	O
).	O

Cells	O
were	O
cultured	O
for	O
48	O
h	O
and	O
pulsed	O
with	O
1	O
µCi	O
[	O
3H	O
]	O
thymidine	O
for	O
the	O
last	O
18	O
h	O
.	O

The	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	O
was	O
measured	O
using	O
a	O
beta	O
-	O
scintillation	O
counter	O
.	O

FTY720	O
treatment	O

Rats	B-OG
were	O
treated	O
with	O
FTY720	O
(	O
generous	O
gift	O
of	O
Novartis	O
AG	O
,	O
Switzerland	O
)	O
and	O
received	O
a	O
daily	O
dose	O
of	O
0	O
.	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
in	O
sterile	O
water	O
by	O
oral	O
gavage	O
as	O
described	O
(	O
Balatoni	O
et	O
al	O
.,	O
2007	O
).	O

This	O
article	O
is	O
part	O
of	O
a	O
special	O
subject	O
collection	O
‘	O
Spotlight	O
on	O
Rat	B-OG
:	O
Translational	O
Impact	O
’,	O
guest	O
edited	O
by	O
Tim	O
Aitman	O
and	O
Aron	O
Geurts	O
.	O

See	O
related	O
articles	O
in	O
this	O
collection	O
at	O
http	O
://	O
dmm	O
.	O
biologists	O
.	O
org	O
/	O
collection	O
/	O
rat	B-OG
-	O
disease	O
-	O
model	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
no	O
competing	O
or	O
financial	O
interests	O
.	O

Author	O
contributions	O

M	O
.	O
M	O
.	O
H	O
.	O
performed	O
the	O
gene	O
arrays	O
,	O
data	O
analysis	O
,	O
target	O
validation	O
in	O
rats	B-OG
and	O
revised	O
the	O
paper	O
.	O

S	O
.	O
B	O
.	O
performed	O
the	O
gene	O
arrays	O
,	O
data	O
analysis	O
and	O
the	O
target	O
validation	O
.	O

B	O
.	O
G	O
.	O
did	O
the	O
work	O
on	O
CD38	B-GP
in	O
mice	B-OG
.	O

K	O
.	O
M	O
.	O
S	O
.	O
performed	O
target	O
validation	O
studies	O
in	O
rats	B-OG
and	O
analyzed	O
the	O
data	O
.	O

A	O
.	O
B	O
.	O
performed	O
studies	O
in	O
individuals	O
with	O
MS	B-DS
and	O
controls	O
.	O

R	O
.	O
W	O
.	O
designed	O
the	O
study	O
,	O
raised	O
the	O
funding	O
,	O
performed	O
the	O
data	O
analysis	O
,	O
and	O
wrote	O
and	O
revised	O
the	O
paper	O
.	O

Funding	O

This	O
study	O
was	O
supported	O
by	O
grants	O
from	O
the	O
Interdisciplinary	O
Centre	O
for	O
Clinical	O
Research	O
(	O
Bundesministerium	O
für	O
Bildung	O
und	O
Forschung	O
)	O
(	O
Fö	O
.	O

01KS9602	O
),	O
and	O
German	O
Research	O
Foundation	O
(	O
Deutsche	O
Forschungsgemeinschaft	O
)	O
to	O
R	O
.	O
W	O
.	O

(	O
DFG	O
We	O
1947	O
).	O

Supplementary	O
information	O

Supplementary	O
information	O
available	O
online	O
at	O
http	O
://	O
dmm	O
.	O
biologists	O
.	O
org	O
/	O
lookup	O
/	O
doi	O
/	O
10	O
.	O
1242	O
/	O
dmm	O
.	O
025536	O
.	O
supplemental	O

